Stimulating the vagus nerve makes platelets stickier and more responsive to clotting signals.
For millions of women, heavy menstrual bleeding remains a condition that medicine has long undertreated and underexplored. Now, a small wearable device that stimulates a nerve branch in the ear is being put to rigorous scientific test — drawing on the body's own clotting pathways to ask whether electricity, applied gently and precisely, might accomplish what pharmaceuticals have struggled to do. The LUNA trial represents not only a promising hypothesis but a quiet reckoning with how seriously women's suffering has historically been taken by the research community.
- Millions of women endure heavy menstrual bleeding with few good options, and the condition quietly erodes daily life through fatigue, pain, and lost functioning.
- A preliminary trial of just 16 women showed blood loss dropping by more than half — a striking signal, but one shadowed by the absence of a control group and the ever-present possibility of placebo effect.
- The LUNA study is now attempting to answer the real question: enrolling 80 women in a fully remote, double-blind, sham-controlled trial designed to strip away expectation and isolate the device's true effect.
- The biological mechanism is specific and testable — vagus nerve stimulation appears to prime platelets for faster clotting through a spleen-mediated chemical chain, a pathway already validated in animal models.
- Researchers are actively recruiting participants aged 14 to 45, and the trial's remote design removes one of the oldest barriers to women's participation in clinical research.
Heavy menstrual bleeding affects millions of women, yet treatment options remain stubbornly limited. Researchers are now testing an unexpected approach: a small wearable device that stimulates a branch of the vagus nerve in the ear, with the goal of making the body's own clotting system work faster and more effectively.
The biological rationale is grounded in real science. Animal studies showed that vagus nerve stimulation changes how platelets behave — through a pathway involving the spleen and a chemical messenger called acetylcholine — reducing wound bleeding by roughly 43 to 46 percent. A preliminary human trial then enrolled 16 women with heavy bleeding and had them use the ear-based device for one-hour sessions twice daily during menstruation. Blood loss scores fell by 54 to 57 percent, periods shortened, and women reported less pain and better quality of life. The caveat is significant: the study was open-label, had no control group, and each woman served as her own baseline across only two cycles. The results are promising but not yet proof.
The LUNA study is designed to provide that proof. It is a randomized, double-blind, sham-controlled trial — the gold standard — enrolling 80 women aged 14 to 45 with heavy periods but no known uterine structural conditions. The trial is conducted entirely remotely, with two baseline cycles followed by three cycles of either active stimulation or sham treatment, two hours per day throughout menstruation. Women track bleeding, pain, and quality of life through validated questionnaires on their own devices.
What gives the trial additional weight is the context surrounding it. Women's health research has long been underfunded, and recruiting women into trials has historically been harder than recruiting men. The decision to move from preliminary data to a rigorous controlled trial — rather than straight to marketing — reflects a standard of scientific integrity that the field has not always applied to conditions affecting women. If the results hold, this could offer a non-medication path for a condition that causes genuine, daily suffering. Researchers are actively recruiting; interested participants can reach Laura Mitchell at LUNA@lindushealth.com or (844) 534-9716.
Heavy menstrual bleeding affects millions of women, and the options to treat it remain frustratingly limited. Now researchers are testing something unexpected: a small wearable device that stimulates a nerve in the ear, based on the theory that doing so could make blood clot faster and reduce flow. The science behind it is real enough to warrant a formal clinical trial, and they're actively recruiting participants right now.
The biological logic starts with the vagus nerve, a major neural highway that runs through the body. Animal studies have shown that electrical stimulation of this nerve changes how platelets behave—the cells responsible for forming blood clots. In pig models, vagus nerve stimulation cut the time needed to stop bleeding from a wound by roughly 43 percent and reduced total blood loss by about 46 percent. The mechanism appears to work through the spleen, where immune cells release acetylcholine, a chemical messenger that binds to platelet receptors and makes them stickier and more responsive to clotting signals. In other words, stimulating the vagus nerve makes platelets more aggressive about forming clots.
A preliminary human trial already tested this concept. Researchers enrolled 16 women—eight with von Willebrand disease, a known bleeding disorder, and eight with heavy bleeding of unknown cause—and had them use a wearable transcutaneous auricular neurostimulation device that targets the vagus nerve branch in the ear. The women used the device for one-hour sessions twice daily during menstruation, and the results were striking: blood loss scores dropped by 54 to 57 percent in both groups, menstruation duration fell by 19 percent, and women reported less cramping, pain, and fatigue alongside improved quality of life. But there's a crucial caveat. This was an open-label study, meaning the women knew they were using the device and there was no control group. With only 16 participants and each woman serving as her own baseline across just two menstrual cycles, the data is preliminary at best. Cycle-to-cycle variation in menstrual bleeding is normal and substantial, so a single comparison doesn't prove the device works. The results are also vulnerable to placebo effect, since women knew they were being treated and self-reported their bleeding using a questionnaire. Still, the signal was strong enough to justify moving forward.
That's where the LUNA study comes in. It's a randomized, double-blind, sham-controlled trial—the gold standard for clinical research—designed to answer whether the device actually works or whether the earlier results were driven by expectation. The study will enroll 80 women aged 14 to 45 with heavy menstrual bleeding but no fibroids or other known uterine conditions. Participants are divided into two age cohorts: adolescents aged 14 to 21 and adults aged 22 to 45. The entire trial is remote, requiring no in-person visits. Women will track their bleeding using the same validated questionnaire used in the earlier study, and they'll also report on pain, other menstrual symptoms, and quality of life. The protocol involves two baseline menstrual cycles with no intervention, followed by three cycles of either active nerve stimulation or sham treatment—a two-hour session each day starting on the first day of menstruation and continuing through the last day of bleeding.
To participate, women must be regularly menstruating, have a documented history of heavy periods, be willing to use only study-provided menstrual products for the duration, and have reliable internet access to complete daily questionnaires on a smartphone or tablet. They also need to maintain stable use of any non-hormonal medications or supplements they're already taking and avoid starting new ones. The study is actively recruiting, and researchers are looking for 80 participants. The contact person is Laura Mitchell at LUNA@lindushealth.com or (844) 534-9716.
What makes this trial noteworthy is not just the science but the approach. Women's health research has historically been underfunded and understudied, and recruiting women for clinical trials has always been harder than recruiting men—partly because women carry greater caregiving responsibilities and partly because of legitimate concerns about side effects and medical mistrust. The fact that a device company is doing the work correctly, moving from preliminary data to a rigorous controlled trial rather than jumping straight to marketing claims, is itself worth noting. If the LUNA study confirms what the earlier trial suggested, it would offer women a non-medication option for a condition that causes real suffering: fatigue, pain, reduced functioning, and diminished quality of life. And if vagal nerve stimulation proves effective for menstrual bleeding, the same mechanism might eventually be applied to other conditions where clotting or immune function matters. For now, the work is in the hands of researchers and the women willing to participate in finding out whether a small device in the ear can make a difference.
Notable Quotes
A Phase 1 study is just that. A fact-finding mission. It is the first step on a long road and responsible researchers don't jump from this point to proclaiming they have a solution on social media.— Dr. Jen Gunter
It's a big deal to have investment in non medication approaches to heavy periods. Considering the magnitude of the problem, the more options we have for women, the better.— Dr. Jen Gunter
The Hearth Conversation Another angle on the story
Why does stimulating a nerve in the ear affect bleeding in the uterus? That seems like it shouldn't work.
It doesn't work directly on the uterus at all. The vagus nerve is like a communication line between the brain and the rest of the body. When you stimulate it, it sends signals to the spleen, which then releases chemicals that make platelets—the cells that form clots—more responsive and sticky. So the effect is systemic, not local.
But why would evolution wire us so that ear stimulation affects clotting? That seems oddly specific.
It's not about ear stimulation specifically. The vagus nerve runs through the ear, but it runs through the whole body. The ear just happens to be accessible without surgery. Animal studies showed the effect works; the ear is just the delivery method.
The first study had only 16 women. How can you trust that?
You can't, not yet. That's why it was Phase I—a proof-of-concept. The results were big enough to justify a real trial, but the earlier study had no control group and women knew they were being treated. Placebo is powerful. The LUNA study will use sham treatment as a control, so we'll actually know if the device works or if women just felt better because they expected to.
What happens if it doesn't work in the bigger trial?
Then we learn something too. We learn the effect was placebo, or that it only works in certain populations, or that something about the earlier study design made the results look better than they were. That's how science moves forward. But the biology is sound enough that it's worth testing properly.
Why does this matter beyond the women in the trial?
Heavy menstrual bleeding affects millions of women and there aren't many good treatment options. Most involve hormones or surgery. A non-medication device, if it works, would give women another choice. And if vagal nerve stimulation does reduce bleeding, it might work for other conditions too.